04 April 2016 : Laboratory Research
Resveratrol Treatment Inhibits Proliferation of and Induces Apoptosis in Human Colon Cancer Cells
Miao FengAB, Lu-Xing ZhongCD, Zheng-Yu ZhanCD, Zhi-Hao HuangCDEF, Jian-Ping XiongDGDOI: 10.12659/MSM.897905
Med Sci Monit 2016; 22:1101-1108
Abstract
BACKGROUND: Resveratrol, a natural isolate from plant sources, has a long and important history in traditional Chinese medicine. In the present study we investigated the effect of resveratrol on human colon cancer cell lines.
MATERIAL AND METHODS: We used the Cell Counting kit-8 (CCK-8) for determination of colon cancer cell viability. Apoptosis induction was analyzed using the DeadEnd™ Colorimetric TUNEL System (Promega, Madison, WI, USA). The siRNA Transfection Reagent kit (Santa Cruz Biotechnology, Inc.) was used for the administration of COX-2 silencer RNA (siRNA) into the colon cancer cells. Primer Express® software for Real-Time PCR ver. 3.0 (Applied Biosystems, Foster City, CA, USA) was used to prepare the primers for RT-PCR.
RESULTS: The results revealed that exposure of colon cancer cells to resveratrol inhibited cell viability. Resveratrol exhibited a significant inhibitory effect on cell viability at 30 μM concentration after 48 h of exposure. We observed that 30-μM doses of resveratrol for 72 h led to 18, 29, and 34% reduction in the viability of HCA-17, SW480, and HT29 cells, respectively. It also significantly induced apoptosis in both of the tested carcinoma cell lines. The population of apoptotic cells in HCA-17 and SW480 cell lines after 48 h of resveratrol treatment was 59.8±4 and 67.2±4%, respectively, compared to 2.3±1% in the control cells. The colon cancer cells exposed to resveratrol showed significantly lower cyclooxygenase-2 and prostaglandin receptor expression. Treatment of colon cancer cells with the inhibitor of cyclooxygenase-2, indomethacin, and administration of silencer RNA for cyclooxygenase-2 also produced similar results.
CONCLUSIONS: These findings suggest that resveratrol treatment can be a promising strategy for the treatment of colon cancer.
Keywords: Cell Proliferation - drug effects, Colonic Neoplasms - pathology, Cyclooxygenase 2 - metabolism, Cyclooxygenase Inhibitors - pharmacology, Dinoprostone - metabolism, Indomethacin - pharmacology, Receptors, Prostaglandin - metabolism, Stilbenes - pharmacology
Editorial
01 July 2026 : Editorial
Editorial: The WHO Identifies Ebola Disease Due to Bundibugyo Virus as a Public Health Emergency of International Concern (PHEIC) as Vaccine Development AcceleratesDOI: 10.12659/MSM.954627
Med Sci Monit 2026; 32:e954627
In Press
Clinical Research
Body Weight and Insulin Resistance Indicators Among ChildrenMed Sci Monit In Press; DOI: 10.12659/MSM.951434
Clinical Research
Comparison of Radiographic Cervical Sagittal Alignment Parameters in Patients With Nonspecific Neck Pain, D...Med Sci Monit In Press; DOI: 10.12659/MSM.952950
Clinical Research
Combined Fibrinogen and Urinary α1-Microglobulin as Predictors of Respiratory Tract Infection in Children w...Med Sci Monit In Press; DOI: 10.12659/MSM.951066
Database Analysis
Evaluation of Salivary Total Oxidant Status (TOS) and Total Antioxidant Status (TAS) in Orthodontic Patient...Med Sci Monit In Press; DOI: 10.12659/MSM.952052
Most Viewed Current Articles
17 Jan 2024 : Review article 14,175,576
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
13 Nov 2021 : Clinical Research 3,756,620
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
14 Dec 2022 : Clinical Research 2,465,966
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 708,651
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387






